SAN DIEGO--(BUSINESS WIRE)--Phenomix Corporation, a drug discovery and development company, announced today the initiation of a Phase 2b clinical trial of PHX1149, an internally-discovered product candidate for the treatment of Type 2 diabetes. The trial is being conducted at multiple sites worldwide and will assess the safety and efficacy of PHX1149 in combination with anti-diabetes medications for Type 2 diabetes. PHX1149 is a novel orally administered inhibitor of the protease dipeptidyl peptidase-4 (DPP4).
